Hypertension, Portal Clinical Trial
Official title:
Prospective Evaluation of Non-invasive ARFI-elastography of Liver and Spleen and Portal Flow Measurement in Comparison With Invasive HVPG (Hepatic Venous Pressure Gradient)-Measurement for Patients With Portal Hypertension.
This study evaluates correlation in changes of HVPG-pressure values and stiffness values (ARFI) for spleen and liver and flow-volume values in Portal vein in patients with liver cirrhosis/Portal Hypertension, respectively, after new-admission of beta-blocker therapy.
Portal Hypertension is the most important risk factor for development of liver cirrhosis-linked complications (e.g. ascites, variceal bleeding, hepatocellular carcinoma, etc.). The invasive HVPG-technique is the standard-of-care Investigation for Evaluation of Portal Hypertension. Administration of Beta-Blocker-therapy results in dropping of the elevated Portal vein pressure values so Overall-survival rate and incidence of liver-cirrhosis-linked complications can be ameliorated. Ultrasound-based Investigation of liver and Spleen-stiffness and of portal-vein-flow-volume, respectively, are the non-invasive methods for Evaluation of Portal Hypertension. But the cut-off values for detection of significant Portal Hypertension by the ultrasound investigation strongly vary depending on the study performed. This study evaluates the changes in ARFI-assisted elastography measurements of liver and spleen and in portal vein flow values, respectively, compared with the recorded Delta in invasive hepatic vein pressure gradient (HVPG)-values for patients with portal hypertension and new administered beta-blocker-therapy. The aim of this study is to evaluate value drop in liver- and Spleen-stiffness and portal-vein-flow required in corelation to a significant drop in HVPG-pressure after new-administered beta-blocker therapy. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03713606 -
Serum Biomarkers for Portal Hypertension in Cirrhosis (Pan-CHESS1802)
|
||
Recruiting |
NCT02505152 -
Percutaneous Transhepatic Intrahepatic Portosystemic Shunt for Treatment of Portal Vein Occlusion With Symptomatic Portal Hypertension After Splenectomy
|
N/A | |
Recruiting |
NCT02504034 -
Interventional Radiology for the Treatment of Symptomatic Portal Hypertension in Patients With Cavernous Transformation of Portal Vein
|
N/A | |
Completed |
NCT02669875 -
Serelaxin To Lower Portal Pressure
|
Phase 2 | |
Recruiting |
NCT04720456 -
SHAPE of Portal Hypertension in Children
|
Phase 2 | |
Completed |
NCT04645550 -
Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy(ESAWAAPT)
|
Phase 4 | |
Recruiting |
NCT02305914 -
Follow-up Study of Complications of Acute Pancreatitis
|
N/A | |
Completed |
NCT01095185 -
Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Cirrhosis and Variceal Bleeding
|
Phase 3 | |
Terminated |
NCT05282121 -
A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)
|
Phase 2 | |
Completed |
NCT00004641 -
A Study to Prevent Complications of High Blood Pressure Caused by Hepatitis in Patients With Cirrhosis
|
Phase 2 | |
Completed |
NCT03138915 -
Radiomics Signature of Hepatic Venous Pressure Gradient (rHVPG) With CT Angiography (CHESS1701)
|
N/A | |
Completed |
NCT03175731 -
PPIs and Gastroesophageal Varices in Liver Cirrhosis (PPIs: Proton Pump Inhibitors)
|
Phase 4 | |
Active, not recruiting |
NCT04315571 -
Comparing Ascites Relief In Two Standard Treatments: Large Volume Paracentesis Vs. Early Tips Using Viatorr Controlled Expansion Stents
|
N/A | |
Completed |
NCT03459378 -
Outcome After TIPS
|
||
Recruiting |
NCT03470389 -
Establishment and Assessment of the HVPG Using Biofluid Mechanics (HVPGBFM)
|
N/A | |
Completed |
NCT02462967 -
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
|
Phase 2 | |
Active, not recruiting |
NCT01097811 -
Comparison Between Erythromycin and Neomycin Treatment of Hepatic Encephalopathy
|
N/A | |
Terminated |
NCT06082843 -
A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly
|
Phase 2 | |
Terminated |
NCT05161481 -
A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Live
|
Phase 2 | |
Completed |
NCT03766880 -
MR-based Models for Clinically Significant Portal Hypertension in Cirrhosis (CHESS1802)
|
N/A |